$19.01
4.85%
Nasdaq, Fri, Dec 27 2024
ISIN
US00211Y4070
Symbol
ABIO
Sector
Industry

ARCA biopharma, Inc. Stock price

$19.01
-1.25 6.17% 1M
-4.22 18.18% 6M
+8.04 73.27% YTD
+8.07 73.78% 1Y
+3.84 25.34% 3Y
-17.65 48.14% 5Y
-744.82 97.51% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.97 4.85%
ISIN
US00211Y4070
Symbol
ABIO
Sector
Industry

Key metrics

Market capitalization $665.32m
Enterprise Value $311.20m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.96
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-36.27m
Free Cash Flow (TTM) Free Cash Flow $-40.25m
Cash position $410.88m
EPS (TTM) EPS $-6.69
P/E forward negative
Short interest 48.08%
Show more

Is ARCA biopharma, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

ARCA biopharma, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a ARCA biopharma, Inc. forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a ARCA biopharma, Inc. forecast:

Buy
100%

Financial data from ARCA biopharma, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.05 0.05
58% 58%
-
- -
-
-
- Selling and Administrative Expenses 10 10
75% 75%
-
- Research and Development Expense 26 26
2,016% 2,016%
-
-36 -36
405% 405%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -36 -36
398% 398%
-
Net Profit -34 -34
535% 535%
-

In millions USD.

Don't miss a Thing! We will send you all news about ARCA biopharma, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ARCA biopharma, Inc. Stock News

Neutral
GlobeNewsWire
4 months ago
The combined company will operate as “Oruka Therapeutics, Inc.” with its common stock traded on Nasdaq under trading symbol “ORKA” effective Tuesday, September 3, 2024 The combined company will operate as “Oruka Therapeutics, Inc.” with its common stock traded on Nasdaq under trading symbol “ORKA” effective Tuesday, September 3, 2024
Neutral
GlobeNewsWire
4 months ago
WESTMINSTER, Colo., Aug. 26, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ: ABIO) (“ARCA”) today announced an update to the previously announced final amount of the special cash dividend (the “Special Dividend”), which will now equal $1.613 per share of ARCA's common stock, payable on August 28, 2024, to ARCA's stockholders of record as of August 26, 2024. The Special Dividend was decla...
Neutral
GlobeNewsWire
4 months ago
WESTMINSTER, Colo., Aug. 23, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ: ABIO) (“ARCA”) today announced that its Board of Directors (the “Board”) has approved a reverse stock split of ARCA's common stock at a ratio of 1-for-12. ARCA's common stock is expected to begin trading on a post-reverse stock split basis on The Nasdaq Global Market on September 3, 2024, under the new name Oruk...
More ARCA biopharma, Inc. News

Company Profile

ARCA biopharma, Inc. is a biopharmaceutical company, which develops genetically targeted therapies for heart failure and other cardiovascular diseases. The company engages in cardiovascular pathophysiology, molecular genetics and clinical development. Its product candidate, Gencaro is a pharmacologic beta-blocker and mild vasodilator, which is developed for the treatment of chronic heart failure and other indications. The company was founded by Michael R. Bristow and Christopher David Ozeroff in 1992 and is headquartered in Westminster, CO.

Head office United States
CEO Lawrence Klein
Employees 5
Founded 1992
Website www.orukatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today